Introduction
============

Cervical cancer is the fourth most frequent malignancy and one of the leading causes of cancer-related death in women, with 527,600 new cases and 265,700 deaths annually worldwide.[@b1-cmar-10-5927],[@b2-cmar-10-5927] In People's Republic of China alone, there are around 19% (98,900 cases) new cases and 12% (30,500 cases) deaths of the total world's cervical cancer burden annually.[@b3-cmar-10-5927] According to the FIGO staging system, about 40% of patients with cervical cancer are diagnosed at early disease stage (stage IA--IIA).[@b4-cmar-10-5927],[@b5-cmar-10-5927] Currently, surgical treatment by RH with bilateral pelvic lymph node dissection is an effective treatment modality for these patients.[@b6-cmar-10-5927]

Since the first publication of a large series of surgeries for cervical cancer by Wertheim in 1912,[@b7-cmar-10-5927] and subsequently by Okabayashi and Meigs, many radical procedures with different degrees of radicality have been described; thereafter, significant progress has been made in the surgical management of cervical cancer.[@b7-cmar-10-5927],[@b8-cmar-10-5927] The salient part of RH is the removal of the lateral parametrium and the upper part of the vagina.

According to Piver et al classification published in 1974, the extent of vaginal resection during RH was recommended to be three-fourths of the vagina;[@b9-cmar-10-5927] however, there was lack of good supporting evidence for this recommendation.[@b10-cmar-10-5927] Based on a lateral extension of resection, Querleu and Morrow described four types (Type A to Type D) of RH in 2008,[@b8-cmar-10-5927] and updated the Querleu--Morrow classification in 2017; the authors also suggested that removal of approximately 10 mm of the tumor-free vaginal cuff is sufficient.[@b11-cmar-10-5927] On the other hand, 1.5--2 cm of the tumor-free vaginal cuff is routinely resected in clinical practice.[@b8-cmar-10-5927]

Some factors have been reported to be prognostic in RH, including tumor size, FIGO stage, nodal status, LVSI, depth of stromal invasion, parametrial involvement, histological type, and adjuvant therapy.[@b12-cmar-10-5927]--[@b15-cmar-10-5927] However, most of the current studies focused on pelvic node metastasis and parametrial invasion; consequently, the knowledge of the VCL to be removed during RH is still limited. Hence, the rationale and role of VCL resection in the prognosis of cervical cancer are less clear. A too short vaginal resection may lead to local recurrence, while excessive removal of the vagina may cause unnecessary complications and seriously reduce the postoperative quality of life.[@b16-cmar-10-5927] So, how much VCL should be resected in order to balance the complications and recurrence? The objective of this study was to reveal the association of VCL with DFS, OS, and local recurrence and distant metastasis rates in patients with cervical cancer following RH.

Methods
=======

Study design and patients
-------------------------

This was a retrospective study that compared long-term survival outcomes of patients with cervical cancer (FIGO stage IB--IIA) who underwent RH with VCL ≤2.0 cm vs VCL \>2.0 cm from January 2007 to February 2017 in Zhongnan Hospital (University Hospital), the Second Clinical College of Wuhan University (Wuhan, People's Republic of China).

The study was carried out according to the Declaration of Helsinki, and informed consent was obtained from all the patients before treatment. Ethical approval was obtained from the Institutional Review Board of the Zhongnan Hospital of Wuhan University.

We hypothesized that VCL during RH is a prognostic factor for cervical cancer and patients with longer VCL have a better survival outcome and a lower rate of recurrence.

To minimize the bias related to surgeons, only the data of patients operated by five senior consultant surgeons with more experience in gynecological oncology procedures were collected. All the patients were reevaluated by two experienced surgeons 1 day before surgery to confirm the FIGO stage.

Clinical and histological data of all the involved patients who underwent surgical treatment were reviewed from patient medical records by two attending physicians. The information included patient demographics, FIGO stage, surgical procedures, tumor histology and grade, lymph node counts and status, tumor size, VCL, margin status, LVSI, parametrial involvement, depth of stromal invasion, use of adjuvant therapy, and follow-up data.

The eligibility criteria for the analyses were as follows: 1) histologically proven cervical cancer of SCC, AC, or ASC; 2) RH with bilateral pelvic and/or para-aortic lymphadenectomy; and 3) negative margin status of surgical specimens. Patients who underwent chemotherapy or radiotherapy before surgery or who received surgical treatment other than RH were excluded. A total of 1355 patients underwent surgical treatment. Of these, 646 patients received chemotherapy or radiotherapy before surgery, while 16 patients received surgical treatment other than RH; further, histological types other than SCC, AC, or ASC were confirmed in 63 patients, 58 patients showed positive margin status, and 137 patients had incomplete data of VCL. Finally, 435 patients were included in this study ([Figure 1](#f1-cmar-10-5927){ref-type="fig"}).

As this was a retrospective study, perfect matching was not possible. Nevertheless, we still compared the two groups according to age, FIGO stage, tumor size, tumor grade, lymph node status, parametrial involvement, LVSI, histological type, and adjuvant therapy.

Histology
---------

Histopathological types were categorized according to the WHO classification. The depth of tumor invasion was categorized by the proportion of the cervical wall invasion by the tumor as medial one-half and lateral one-half. LVSI was defined as the presence of neoplastic cells within endothelium-lined spaces. The histopathological diagnosis of the surgical specimen was completed and confirmed by at least two pathologists. Moreover, for the purpose of this study, all the pathological slides were reevaluated blindly by another experienced gynecological pathologist.

Measurement of VCL and tumor size
---------------------------------

After RH, the surgical specimens were handled in a standardized manner immediately. An attending surgeon made a ventral Y-shaped incision from the uterine fundus to the vaginal cuff on the specimen, and the VCL and tumor size were then measured. The VCL was measured on a fresh sample without stretching; it is the minimum distance between the edge of the cervix or tumor (the edge of the cervix for stage IB and the edge of tumor for stage IIA) and resection margin.

Patient follow-up
-----------------

All patients were followed up every 3 months in the first 2 years and then subsequently every 6 months. Pelvic and cytological examinations were performed at every visit. CT or MRI was performed in every 12 months or when clinically indicated. The end point was the time from the start of surgery to the earliest diagnosis of recurrence or death.

Study outcomes
--------------

The primary end points of this study were local recurrence, distant metastasis, DFS, and OS. The time to local recurrence was calculated from the date of surgery to the date of first documented primary recurrence. The time to distant metastasis was calculated from the date of surgery to the date of first documented distant metastasis. DFS was defined as the time from the date of surgery to the date of death or recurrence, either local recurrence or distant metastasis. OS was computed from the date of surgery to the date of death or last follow-up.

Recurrence assessment
---------------------

Recurrence case was diagnosed during the regular followup visit and mainly confirmed by CT and/or MRI. Whenever possible, histological or cytological confirmation was obtained. Sites of recurrence were classified as local and distant. Local recurrence included central (ie, around the vaginal stump or paracolpium) or pelvic sidewall. Distant metastasis was defined as tumor recurrence at a site beyond the pelvic radiation field. Para-aortic lymph node or other distant node metastases were defined as distant metastases.

Statistical analysis
--------------------

Participants and tumor characteristics were grouped according to VCL. Chi-squared tests or Fisher's exact tests were used to compare the categorical variables between the VCL groups. Student's *t*-tests were used to compare continuous variables such as age and number of lymph nodes. The survival outcomes (local recurrence, distant metastasis, DFS, and OS) were estimated according to VCL and compared using the Kaplan--Meier method and log-rank statistic, respectively. Cox proportional hazards regression models were used to estimate the relative likelihood of DFS and OS with various factors in both univariate and multivariate analyses. Variables with a probability value \<0.10 were included in a Cox multivariate proportional hazards regression analysis. Several additional variables were selected for the multivariate analysis according to literature (ie, LVSI and histological type). The results are presented as HRs with 95% CIs. A *P*-value of \<0.05 was considered to be statistically significant. Statistical analysis was performed using the SPSS 16.0 statistical package (version 16.0; SPSS Inc., Chicago, IL, USA).

Results
=======

Clinical and pathological characteristics
-----------------------------------------

[Table 1](#t1-cmar-10-5927){ref-type="table"} presents the clinical and pathological characteristics of the included patients. The median age at diagnosis was 44 years (range 21--68 years), and the median follow-up time was 60 months (range 12--122 months). Of the included patients, 269 (61.8%) were diagnosed as having FIGO stage IB cervical cancer, and 367 (84.4%) had squamous cell carcinoma. The median number of lymph nodes removed was 24 (range 12--45), and lymph node positive rate was 18.6%. Forty-six patients (10.6%) had parametrial involvement, and LVSI was present in 164 patients (37.7%). In \>50% of the patients, the depth of stromal invasion was ≤1/2. Adjuvant therapy was administered in 47.4% of the patients, and 45--50 Gy of external beam pelvic radiation therapy was administered to the patients who underwent chemoradiotherapy or radiotherapy alone followed by surgery.

The patients with a longer VCL were more likely to be in an advanced FIGO stage (*P*=0.031). Moreover, patients with VCL \>2.0 cm showed a significant higher depth of stromal invasion than patients with VCL ≤2.0 cm (*P*=0.001). In addition, in the group of longer VCL, parametrial involvement was also more commonly observed (*P*=0.035). Around 50% (120/239) of patients with VCL \>2.0 cm received adjuvant therapy as compared to 44% (86/196) of those with VCL ≤2.0 cm. The distribution of other clinicopathological characteristics (tumor grade, maximal tumor size, and histological type) was not statistically associated with VCL.

Survival analysis based on VCL
------------------------------

There were 60 (30.6%) vs 28 (11.7%) recurrences (*P*\<0.001) and 53 (27.0%) vs 22 (9.2%) deaths (*P*\<0.001) in the VCL ≤2.0 cm and VCL \>2.0 cm groups, respectively. We analyzed the survival data of these patients by the Kaplan--Meier analysis to understand the clinical significance of VCL in RH. For all the 435 patients with cervical cancer, the overall 5-year DFS and OS were 78.7% (95% CI: 74.4%--83.0%) and 81.1% (95% CI: 77.0%--85.2%), respectively.

In the VCL \>2.0 cm group, the 5-year DFS was 87.5%, which was significantly higher than that of the VCL ≤2.0 cm group (68.1%; *P*\<0.001; [Figure 2A](#f2-cmar-10-5927){ref-type="fig"}). Similarly, the 5-year OS was 89.2% and 71.4% for the VCL \>2.0 cm and VCL ≤2.0 cm groups, respectively (*P*\<0.001; [Figure 2B](#f2-cmar-10-5927){ref-type="fig"}). We also used the Kaplan--Meier analysis to assess the impact of VCL on postoperative local and distant recurrence rate. The 5-year local recurrence rate was 10.9% and 26.9% for the VCL \>2.0 cm and VCL ≤2.0 cm groups, respectively (*P*\<0.001; [Figure 2C](#f2-cmar-10-5927){ref-type="fig"}), while the 5-year distant metastasis rate was 5.0% and 6.9% for the VCL \>2.0 cm and VCL ≤2.0 cm groups, respectively (*P*=0.212; [Figure 2D](#f2-cmar-10-5927){ref-type="fig"}).

Univariate and multivariate Cox regression analysis
---------------------------------------------------

Univariate analysis suggested that VCL, FIGO stage, maximal tumor size, depth of stromal invasion, positive lymph node status, parametrial involvement, and adjuvant therapy were significantly associated with both DFS and OS ([Table 2](#t2-cmar-10-5927){ref-type="table"}).

For the multivariate Cox proportional hazards models, the variates were selected according to the univariate analyses. Consequently, as shown in [Table 3](#t3-cmar-10-5927){ref-type="table"}, independent prognostic factors of cervical cancer for DFS were VCL ≤2.0 cm (HR 4.344 \[95% CI: 2.695--7.000\]), FIGO stage (HR 4.942 \[95% CI: 2.467 -- 9.898\]), and positive lymph node status (HR 3.711 \[95% CI: 2.383--5.778\]). Further, the independent prognostic factors in the multivariate analysis for OS were VCL ≤2.0 cm (HR 4.830 \[95% CI: 2.849--8.190\]), FIGO stage IIA2 (HR 5.228\[95% CI: 2.487 -- 10.989\]), and positive lymph node status (HR 4.021 \[95% CI: 2.449--6.472\]).

Discussion
==========

In our study, we found that VCL was strongly associated with 5-year DFS and OS in patients with cervical cancer (FIGO stage IB--IIA). The 5-year DFS and OS were significantly higher in women with VCL \>2 cm (*P*\<0.001). Moreover, the 5-year local recurrence rate was also significantly lower in women with VCL \>2 cm (*P*\<0.001). However, there was no significant association between the 5-year distant metastasis rate and VCL (*P*=0.212). Our findings are consistent with prior qualitative studies which reported that the closer margin status was associated with higher rate of recurrence or local recurrence as shown by Viswanathan et al; their survey also showed that the relapse-free survival rate was increased with each millimeter increase in distance from the tumor.[@b17-cmar-10-5927] Similarly, another study reported that surgical margins of \<5 mm are often associated with recurrence in the presence of other high- or intermediate-risk factors.[@b18-cmar-10-5927] Though the primary focus of the above studies was on surgical margin rather than on VCL, their conclusions may provide an explanation for our results.

On the other hand, in contrast to our findings, Kim et al reported in 2011 that VCL was not associated with vaginal and pelvic recurrence rates in patients with cervical cancer following RH.[@b10-cmar-10-5927] They assessed the 3-year vaginal and pelvic recurrence rate in 280 Korean women with a majority of them having stage IB1 (73.2%) cervical cancer and 68% of the participants had received adjuvant therapy. A more recent study conducted by Edwards et al in 2015 also reported that VCL was not associated with vaginal and pelvic recurrence among patients with cervical cancer. They analyzed the data of 169 patients with stage IB1 cervical cancer with a median follow-up time of 12 years.[@b19-cmar-10-5927] Both these studies primarily evaluated patients with stage IB1 disease, and their end result was vaginal and pelvic recurrence. Results of the present study may have been affected by a greater proportion of patients with more advanced disease (stage IB2--IIA2, 73%), a lower percent of patients received adjuvant therapy, and a relatively longer follow-up period (up to 10 years). These might be the potential reasons that explain the association between VCL and local recurrence, DFS, and OS.

Currently, there is no uniform standard for the length of vaginal resection during RH. Different surgical classification methods of RH are also controversial about the recommended length of vaginal resection. The classic Piver et al classification, published in 1974, described five classes of extended hysterectomies for women with cervical cancer, in which the vaginal resection was excessive (one-third to three-quarters of the vagina).[@b8-cmar-10-5927] In addition, the current updated Querleu--Morrow classification of RH is based only on the lateral extent of parametrium resection, which proposed four types (A--D) of RH with detailed description on the lateral resection part, but not a clear recommendation for VCL.[@b8-cmar-10-5927],[@b11-cmar-10-5927] In Type C that is indicated for FIGO stage IB--IIA, they have proposed "the length of the vaginal cuff is adjusted to the vaginal extent of the tumor".[@b11-cmar-10-5927]

There should also be an optimal range for the length of the vaginal resection during RH. A study on TMMR, in which the embryologically defined uterovaginal compartment was removed in patients with cervical cancer (stage IB--IIA and selected IIB), found that TMMR is pivotal in pelvic control.[@b4-cmar-10-5927] Though not conclusive, as a part of the TMMR, the recommended safe margin for vaginal cuff resection was 1--1.5 cm. However, Zullo et al reported that significantly longer length of vaginal resection in RH was associated with detrusor dysfunction, thereby causing urine storage and voiding problem.[@b16-cmar-10-5927] In our study, we consider that the most appropriate VCL could be \>2 cm for cervical cancer (FIGO stage IB--IIA). However, our study was unable to determine an optimal ceiling for VCL, which is a limitation of this study.

Apart from VCL, we also identified FIGO stage and lymph node involvement as significant prognostic factors for cervical cancer. It is known that the locally advanced stage is an unfavorable prognostic factor of cervical cancer.[@b20-cmar-10-5927] Moreover, recent studies have reported that the FIGO stage was an independent prognostic factor for the risk of both recurrence and death.[@b21-cmar-10-5927],[@b22-cmar-10-5927] In our study, patients with stage II cervical cancer showed significantly unfavorable OS (HR 2.320 \[95% CI: 1.438--3.745\]) compared to patients in stage I (data not shown).

This is a single institution-based retrospective study; and hence, some limitations are present. There might be other confounding variables apart from VCL that could also have played a role in prognosis and recurrence. Apart from possible clinicopathological factors, other confounding factors include age, height, weight, and menopause. These factors may influence the measurement of vaginal length.[@b23-cmar-10-5927] A large number of patients were excluded from the analysis because of having incomplete data. In addition, as histological biopsies are invasive procedures and require informed consent from patients, only a small number of patients agreed to receive histological examination. Despite these limitations, this is a large comprehensive study with encouraging result to evaluate the 5-year DFS and OS for patients with cervical cancer (stage IB--IIA) based on VCL following RH.

Conclusion
==========

VCL is an important prognostic factor, and VCL \>2 cm is a favorable factor for DFS and OS in patients with cervical cancer (FIGO stage IB--IIA). In addition, VCL \<2 cm also significantly increases the risk of local recurrence of cervical cancer. A well-designed multicenter study with an adequate sample size is recommended to validate VCL as a prognostic factor and to define the VCL cutoff value in RH for cervical cancer (FIGO stage IB--IIA).
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###### 

Summary of clinical and pathological characteristics (n=435)

  Characteristics                    VCL (cm)        Mean or total   *P*-value        
  ---------------------------------- --------------- --------------- ---------------- -------
                                                                                      
  Age (years)                                                                         
   Mean (range)                      45.5 (21--67)   44.2 (21--68)   44.80 (21--68)   0.290
  Number of lymph node                                                                
   Mean (range)                      25.3 (12--45)   24.6 (12--45)   24.9 (12--45)    0.313
  FIGO stage, n (%)                                                                   
   Stage IB1                         64 (32.7)       54 (22.6)       118 (27.1)       0.031
   Stage IB2                         69 (35.2)       82 (34.3)       151 (34.7)       
   Stage IIA1                        45 (23.0)       64 (26.8)       109 (25.1)       
   Stage IIA2                        18 (9.2)        39 (16.3)       57 (13.1)        
  Tumor grade, n (%)                                                                  
   G1                                51 (26.0)       56 (23.4)       107 (24.6)       0.822
   G2                                90 (45.9)       114 (47.7)      204 (46.9)       
   G3                                55 (28.1)       69 (28.9)       124 (28.5)       
  Maximal tumor size, n (%)                                                           
   \<2 cm                            41 (20.9)       58 (24.3)       99 (22.8)        0.055
   2--4 cm                           70 (35.7)       60 (25.1)       130 (29.9)       
   \>4 cm                            85 (43.4)       121 (50.6)      206 (47.4)       
  Depth of stromal invasion, n (%)                                                    
   ≤1/2                              117 (59.7)      104 (43.5)      221 (50.8)       0.001
   \>1/2                             79 (40.3)       135 (56.5)      214 (49.2)       
  Lymph node status, n (%)                                                            
   Negative                          165 (84.2)      189 (79.1)      354 (81.4)       0.174
   Positive                          31 (15.8)       50 (20.9)       81 (18.6)        
  Parametrial involvement, n (%)                                                      
   No                                182 (92.9)      207 (86.6)      389 (89.4)       0.035
   Yes                               14 (7.1)        32 (13.4)       46 (10.6)        
  LVSI, n (%)                                                                         
   No                                131 (66.8)      140 (58.6)      271 (62.3)       0.077
   Yes                               65 (33.2)       99 (41.4)       164 (37.7)       
  Histology, n (%)                                                                    
   SCC                               168 (85.7)      199 (83.3)      367 (84.4)       0.484
   AC or ASC                         28 (14.3)       40 (16.7)       68 (15.6)        
  Adjuvant therapy, n (%)                                                             
   No                                110 (56.1)      119 (49.8)      229 (52.6)       0.188
   Yes                               86 (43.9)       120 (50.2)      206 (47.4)       
  Recurrence disease, n (%)                                                           
   Locoregional only                 46 (76.7)       16 (57.1)       62 (70.5)        0.008
   Distant only                      11 (18.3)       4 (14.3)        15 (17.0)        
   Locoregional plus distant         3 (5.0)         8 (28.6)        11 (12.5)        

**Abbreviations:** AC, adenocarcinoma; ASC, adenosquamous carcinoma; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; SCC, squamous cell carcinoma; VCL, vaginal cuff length.

###### 

Univariate Cox regression analysis of prognostic factors of cervical cancer

  Variables                   DFS     OS                                              
  --------------------------- ------- -------------- --------- ------- -------------- ---------
                                                                                      
  Age, 1-year increment       0.989   0.972--1.005   0.169     0.989   0.972--1.007   0.245
  VCL \>2.0 cm                Ref.                             Ref.                   
  VCL ≤2.0 cm                 2.940   1.876--4.608   \<0.001   3.207   1.949--5.275   \<0.001
  Stage IB1                   Ref.                             Ref.                   
  Stage IB2                   2.288   1.209--4.328   0.011     2.225   1.120--4.210   0.022
  Stage IIA1                  2.195   1.127--4.273   0.021     1.882   0.905--3.912   0.090
  Stage IIA2                  4.193   2.129--8.257   \<0.001   4.313   2.090--8.899   \<0.001
  Grade G1                    Ref.                                                    
  Grade G2                    1.304   0.760--2.239   0.335     1.495   0.808--2.765   0.200
  Grade G3                    1.182   0.654--2.137   0.579     1.505   0.778--2.910   0.224
  Size \<2 cm                 Ref.                             Ref.                   
  Size 2--4 cm                2.822   1.340--5.946   0.006     2.949   1.270--6.845   0.012
  Size \>4 cm                 3.443   1.689--7.018   0.001     3.979   1.790--8.846   0.001
  Depth of stromal invasion   1.667   1.092--2.547   0.018     2.005   1.256--3.203   0.004
  Lymph node status           3.322   2.166--5.095   \<0.001   3.514   2.218--5.569   \<0.001
  Parametrial involvement     2.383   1.403--4.047   0.001     2.505   1.422--4.414   0.001
  LVSI                        1.114   0.727--1.708   0.620     1.175   0.742--1.860   0.493
  Histology                   1.387   0.826--2.328   0.216     1.342   0.762--2.363   0.308
  Adjuvant therapy            1.619   1.056--2.482   0.027     1.719   1.080--2.737   0.022

**Abbreviations:** DFS, disease-free survival; LVSI, lymphovascular space invasion; OS, overall survival; VCL, vaginal cuff length.

###### 

Multivariate analysis of prognostic factors of cervical cancer

  Variables           DFS     OS                                               
  ------------------- ------- -------------- --------- ------- --------------- ---------
                                                                               
  VCL \>2.0 cm        Ref.                             Ref.                    
  VCL ≤2.0 cm         4.344   2.695--7.000   \<0.001   4.830   2.849--8.190    \<0.001
  Stage IB1           Ref.                             Ref.                    
  Stage IB2           1.981   1.043--3.763   0.037     1.918   0.961--3.829    0.065
  Stage IIA1          2.149   1.092--4.228   0.027     1.800   0.857--3.780    0.121
  Stage IIA2          4.942   2.467--9.898   \<0.001   5.228   2.487--10.989   \<0.001
  Lymph node status   3.711   2.383--5.778   \<0.001   4.021   2.499--6.472    \<0.001

**Abbreviations:** DFS, disease-free survival; OS, overall survival; VCL, vaginal cuff length.
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